SEC Form 4 · accession 0001104659-19-006898
STEMLINE THERAPEUTICS INC · STML
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kenneth Hoberman
Officer — Chief Operating Officer
Period of report
Feb 6, 2019
Accepted (ET)
Feb 8, 2019 · 8:54 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001264587
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Feb 6, 2019 | A | 135,071 | $0.00 | A | 781,723 | D | |
| Common StockF3,F4 | Feb 6, 2019 | A | 13,607 | $0.00 | A | 795,330 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The 135,071 restricted shares will vest in three installments as follows: 45,024 shares on January 21, 2020; 45,024 shares on April 13, 2021; and 45,023 shares on March 29, 2022.
- F2Of the 781,723 shares, 604,061 shares are restricted stock.
- F3The 13,607 restricted shares will vest in two installments as follows: 6,804 shares on December 21, 2019 and 6,803 shares on December 21, 2020.
- F4Of the 795,330 shares, 617,668 shares are restricted stock.